Allarity Therapeutics Stock (NASDAQ:ALLR)



Previous Close

$0.98

52W Range

$0.90 - $264.00

50D Avg

$1.09

200D Avg

$5.99

Market Cap

$4.34M

Avg Vol (3M)

$1.89M

Beta

0.25

Div Yield

-

ALLR Company Profile


Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

5

IPO Date

Dec 21, 2021

Website

ALLR Performance


ALLR Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-20.42M$-34.46M$-26.56M
Net Income$-20.42M$-16.06M$-26.65M
EBITDA$-20.42M$-16.80M$-28.27M
Basic EPS$-0.01$-2.06$-167.62
Diluted EPS$-0.01$-2.06$-167.62

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
BDRXBiodexa Pharmaceuticals Plc
ZVSAZyVersa Therapeutics, Inc.
PHIOPhio Pharmaceuticals Corp.
CNSPCNS Pharmaceuticals, Inc.
VRAXVirax Biolabs Group Limited
IMMXImmix Biopharma, Inc.
QNRXQuoin Pharmaceuticals, Ltd.
SONNSonnet BioTherapeutics Holdings, Inc.
ZURAZura Bio Limited